CI

At a glance

ClinicalIndex Comparison Record
Phase 2Not Yet Recruiting· 220 target
Drug / intervention
JSKN016 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06775483
NCT06775483Phase 2Not Yet Recruiting
CompareCT.gov

Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance： a Phase II Clinical Study

Jiangsu Alphamab Biopharmaceuticals Co., Ltd·interventional·Posted Jan 15, 2025·Updated Jan 15, 2025

In Brief

A Phase 2 clinical trial evaluating JSKN016 and Docetaxel for Advanced Non-small Cell Lung Cancer. Not yet recruiting, targeting 220 participants.

Detailed Summary

This is a Phase II clinical study conducted in China to evaluate the treatment of advanced non-small cell lung cancer with JSKN016. The enrolled subjects are all in the locally advanced or metastatic stage of non-small cell lung cancer.The study is divided into two parts. The main objective of part I is to assess the efficacy and safety of JSKN016 in selected subjects with advanced non-small cell lung cancer. The main objective of part II is to compare the efficacy of JSKN016 and docetaxel in subjects with advanced non-small cell lung cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Non-small Cell Lung Cancer
Countries--
Collaborators--

Timeline

Phase 2Not Yet Recruiting
2025202620272028
First PostedJan 15, 2025
Enrollment StartJan 17, 2025
Primary CompletionJun 30, 2027
Study CompletionNov 30, 2027
TodayJul 1, 2026
Enrollment to primary: 2.5 yearsPosted 1.5 years agoPrimary completion in 12 months

Interventions

JSKN016drug

Administered intravenously according to protocol.

Docetaxeldrug

Administered intravenously according to protocol.